Drugs.com - Clinical Trials

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for...

Feb 9, 2025 - 23:19
 0
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for...
Read More

Tags:

Previous Article

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosu...

Next Article

Trump set to impose steel, aluminium tariffs

Related Posts

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces FDA Fast Track and Enrollment U...

Feb 27, 2025  0

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

Findings From Pivotal Nipocalimab Phase 3 Study in a Br...

Feb 9, 2025  0

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Receives FDA Fast Track Designation for ADI-...

Feb 9, 2025  0